- Home
- EMO vs IMTX Comparison
EMO vs IMTX Comparison
Compare EMO & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMO
- IMTX
- Stock Information
- Founded
- EMO 2011
- IMTX N/A
- Country
- EMO United States
- IMTX Germany
- Employees
- EMO N/A
- IMTX N/A
- Industry
- EMO Investment Managers
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EMO Finance
- IMTX Health Care
- Exchange
- EMO Nasdaq
- IMTX Nasdaq
- Market Cap
- EMO 599.1M
- IMTX 579.8M
- IPO Year
- EMO N/A
- IMTX N/A
- Fundamental
- Price
- EMO $45.97
- IMTX $4.56
- Analyst Decision
- EMO
- IMTX Strong Buy
- Analyst Count
- EMO 0
- IMTX 4
- Target Price
- EMO N/A
- IMTX $16.67
- AVG Volume (30 Days)
- EMO 27.1K
- IMTX 419.9K
- Earning Date
- EMO 01-01-0001
- IMTX 05-20-2025
- Dividend Yield
- EMO 6.70%
- IMTX N/A
- EPS Growth
- EMO N/A
- IMTX N/A
- EPS
- EMO N/A
- IMTX 0.14
- Revenue
- EMO N/A
- IMTX $161,336,577.00
- Revenue This Year
- EMO N/A
- IMTX N/A
- Revenue Next Year
- EMO N/A
- IMTX $4.92
- P/E Ratio
- EMO N/A
- IMTX $31.46
- Revenue Growth
- EMO N/A
- IMTX 188.60
- 52 Week Low
- EMO $26.42
- IMTX $3.30
- 52 Week High
- EMO $40.17
- IMTX $13.77
- Technical
- Relative Strength Index (RSI)
- EMO 52.94
- IMTX 50.27
- Support Level
- EMO $44.01
- IMTX $3.94
- Resistance Level
- EMO $45.96
- IMTX $5.41
- Average True Range (ATR)
- EMO 0.98
- IMTX 0.37
- MACD
- EMO 0.19
- IMTX -0.03
- Stochastic Oscillator
- EMO 78.09
- IMTX 42.18
About EMO ClearBridge Energy Midstream Opportunity Fund Inc.
ClearBridge Energy Midstream Opportunity Fund Inc is a non-diversified, closed-end management investment company. Its investment objective is to provide long-term investors with a high level of total return with an emphasis on cash distributions.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.